1008 / 1851
RTOG 0617 – Conclusions
“
Positive” of RTOG 0617
•
Excellent median survival of 28.7 months in the 60-Gy study arms when
compared with prior cooperative group studies in stage III NSCLC.
•
May reflect PET scan use for staging (used in ~ 90% of pts)
“
Negative” of RTOG 0617
•
74 Gy radiation with concurrent CT was not better than 60 Gy for patients with
stage III NSCLC, and might be potentially harmful.
•
Addition of Cetuximab to concurrent CR-RT and consolidation treatment
provided no benefit in OS for these patients, but increased overall grade 3-5
toxicity (85% vs 69%, p < 0.0001)